Ardelyx Showcases Key Findings for XPHOZAH in Kidney Disease
Ardelyx Showcases Key Findings for XPHOZAH in Kidney Disease
Ardelyx, Inc. (Nasdaq: ARDX), based in Waltham, Massachusetts, is on a mission to bring innovative treatments to individuals facing significant health challenges. Recently, the company announced their plan to present important data related to XPHOZAH® (tenapanor) at the esteemed American Society of Nephrology's Kidney Week event. This year, the event will take place from October 24-27, showcasing advancements in the management of chronic kidney disease (CKD).
What is XPHOZAH?
XPHOZAH is a pioneering phosphate absorption inhibitor that has gained approval from the U.S. Food and Drug Administration. It specifically targets adults with CKD who are on dialysis, providing an essential addition for patients who do not respond adequately to phosphate binders or experience adverse effects from them. Administered as a single tablet taken twice daily, XPHOZAH operates through a unique mechanism that disrupts phosphate absorption in the intestines.
Presentation Highlights at Kidney Week
During the Kidney Week, Ardelyx will share compelling insights through two significant poster presentations. One study emphasizes the association between sustained phosphate reduction with tenapanor and decreased levels of fibroblast growth factor 23 in patients experiencing hyperphosphatemia while on dialysis. The second poster demonstrates that the efficacy and tolerability of tenapanor remain consistent when incorporated alongside different phosphate binders.
Innovative Management Discussion
In addition to the poster presentations, Ardelyx will sponsor an engaging Exhibitor Spotlight entitled “A Different Perspective on Hyperphosphatemia Management: Evaluating Current Strategies.” This session, occurring on October 25, will feature Dr. Steven Fishbane, who will delve deeper into the benefits of XPHOZAH.
Understanding Hyperphosphatemia
Hyperphosphatemia is a critical condition characterized by elevated phosphate levels in the blood, affecting countless patients with chronic kidney disease undergoing maintenance dialysis. As kidney function decreases, the body struggles to eliminate excess phosphate, leading to complications that can severely impact overall health. Therefore, managing phosphate levels effectively is imperative, as recommended by KDIGO guidelines.
Safety Information for XPHOZAH
While XPHOZAH offers vital benefits for managing phosphate levels, it also comes with essential safety considerations. Specifically, it is contraindicated in pediatric patients under six years of age and those with known gastrointestinal obstructions. Furthermore, severe diarrhea was noted as the most common adverse reaction, occurring in a significant percentage of clinical trial participants. Thus, patients are advised to discontinue XPHOZAH if they experience severe diarrhea during treatment.
About Ardelyx and Its Commitment
Ardelyx is dedicated to discovering, developing, and commercializing groundbreaking medicines like XPHOZAH and its other product, IBSRELA® (tenapanor). With their commitment to addressing unmet medical needs, Ardelyx has formed various collaborations to expand the reach of its products beyond the U.S., including partnerships in Japan and China.
Investor and Media Inquiries:
Caitlin Lowie
Contact: clowie@ardelyx.com
Frequently Asked Questions
What is XPHOZAH and its purpose?
XPHOZAH is a first-in-class phosphate absorption inhibitor approved for reducing serum phosphorus in adults with CKD on dialysis.
Where will Ardelyx present the data?
The data will be presented at the American Society of Nephrology's Kidney Week, an event dedicated to advancements in nephrology.
What are the side effects of XPHOZAH?
The most common side effect reported is diarrhea, which affected a notable percentage of patients in clinical trials.
Is XPHOZAH suitable for all patients with CKD?
No, it is contraindicated in pediatric patients under six and those with specific gastrointestinal conditions.
What does Ardelyx aspire to achieve?
Ardelyx aims to provide innovative treatments that meet significant unmet medical needs through their products like XPHOZAH and IBSRELA.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- S&P 500 Set to Surpass 6,000 Amid Earnings Growth Projections
- Investigation Launched into Nabors Industries Merger and Fairness
- Challenges and Opportunities in Improving U.S. Retirement System
- Kiro Race Co: A Fresh Start in the ABB FIA Formula E Championship
- Why Saudi Arabia Might Increase Oil Production Soon
- Paymentus Innovations Revolutionize Insurance Claims Payments
- Walgreens Boots Alliance Sees Growth Amid Cost-Cutting Efforts
- Investigation Launched for Investors of Sprinklr, Inc. Claims
- The Impact of the Bala Sustainability Index on Construction Projects
- Resolute Investment Managers Welcomes Ted Wozniak as Vice President
Recent Articles
- Mandalay Resources Welcomes John Jentz to Board of Directors
- Xtreme One Entertainment Opens New Doors for Investors with Stock Offering
- Nevada King Gold Corp. Names John Sclodnick New President
- Logicalis Unveils Sustainable IT Strategy for Carbon Neutrality
- Unlocking Service Efficiency: QLESS Introduces Service Intelligence
- Landstar to Share Q3 Results and Conference Call Details Soon
- Innovative Approaches in Obesity Treatment Discussed by ZyVersa CEO
- GoGold's Impressive Quarterly Production Exceeds Expectations
- LONGi Launches Innovative Hi-MO X10 Modules at Shanghai Event
- BriaCell Advances Pivotal Study for Metastatic Breast Cancer Therapy
- AVS Initiates Pivotal Study for Intravascular Treatment
- Nova Leap Health Corp. Expands Its Presence in Florida Market
- Mexico's Path to Growth: Embracing Nearshoring Opportunities
- Breast Cancer Awareness Month: Biotechnology Innovations for Women
- Dr. Danninger Joins Circus Group Board to Revolutionize Robotics
- Epitomee Medical Unveils Innovative Oral Delivery at PODD 2024
- Alpha Metallurgical Delivers Positive Preliminary Q3 Results
- Discover Epitomee Medical's Innovative Oral Delivery Solutions
- DermCare Management Strengthens California Expansion with New Partner
- Jazz Pharmaceuticals Advances Lung Cancer Treatment with Zepzelca
- Consumer Trust in CVS Health Pharmacists Shows Strong Trends
- Lucid Diagnostics Achieves Patent Allowance for Innovative Cancer Test
- CECO Environmental Expands Credit Facility for Growth Plans
- Ocular Therapeutix Accelerates AXPAXLI Trial Timeline for AMD
- Merit Medical Systems: Price Target Raised Amid Strong Growth Prospects
- Uber's Strategy Faces New Challenges in Robotaxi Market
- GoDaddy Maintains Strong Buy Rating with Increased Price Target
- MRC Global's Strategic Moves to Enhance Capital Structure
- Molecure and Ocean Biomedical Unite for $32M Cancer Therapy Venture
- Alpha Metallurgical Resources Highlights Q3 Preliminary Outcomes
- Exploring the Growth of the Electric Truck Industry's Future
- Baird Raises FIS Price Target, Anticipating Strong Q3 Performance
- Swvl's Regional HQ in Riyadh: A Strategic Growth Move
- Baird Maintains Positive Outlook on Global Payments Stock Value
- Webinar on Genetic Validation for Cardiovascular Treatments
- Boeing's Strategic Move: $25 Billion Shelf Registration Filed
- Goldman Sachs Shows Strong Growth: A Delight for Investors
- Watsco Plans Key Conference Call for Third Quarter Results
- Charles Schwab Sees Share Growth After Impressive Q3 Results
- Stock Market Updates: Major Movements in US Equities Today
- Attovia Therapeutics Welcomes New CFO Steven Chan
- BullFrog AI Welcomes Dr. John Baldoni to Advisory Board
- Bombardier's Upcoming Financial Presentation Details
- Navigating Market Trends with the New Eckhardt Fund
- Edge One Capital's Bold Move to Revamp BuzzFeed's Leadership
- Exploring Dashboard Camera Market Growth Amid Insurance Fraud
- Electric Truck Industry on the Rise: Insights and Innovations
- NatureSweet's Delightful Celebration of Día de Muertos Unveiled
- GoGold Achieves Significant Production Milestones in Latest Quarter
- UnitedHealth Group Surprises with Q3 Performance and Outlook